Back to Journals » Cancer Management and Research » Volume 12

The Novel Zinc Finger Protein 587B Gene, ZNF587B, Regulates Cell Proliferation and Metastasis in Ovarian Cancer Cells in vivo and in vitro

Authors Liu Y, Ouyang Q, Sun Z, Tan J, Huang W, Liu J, Liu Z, Zhou H, Zeng F, Liu Y

Received 3 March 2020

Accepted for publication 2 June 2020

Published 26 June 2020 Volume 2020:12 Pages 5119—5130

DOI https://doi.org/10.2147/CMAR.S252347

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Ahmet Emre Eskazan


Yujie Liu,1,2 Qianying Ouyang,1,2 Zeen Sun,1,2 Jieqiong Tan,3 Weihua Huang,1,2 Jie Liu,1,2 Zhaoqian Liu,1,2 Honghao Zhou,1,2 Feiyue Zeng,4,* Yingzi Liu1,2,*

1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People’s Republic of China; 2Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, People’s Republic of China; 3National Laboratory of Medical Genetics, Central South University, Changsha 410078, People’s Republic of China; 4Department of Radiology, Xiangya Hospital, Central South University, Changsha 410008, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Yingzi Liu
Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, People’s Republic of China
Tel +86 731 84805380
Fax +86 731 82354476
Email yzlcsu@csu.edu.cn
Feiyue Zeng
Department of Radiology, Xiangya Hospital, Central South University, Changsha 410008, People’s Republic of China
Tel +86 731 84805380
Fax +86 731 82354476
Email feiyuezeng@163.com

Background: The zinc finger protein 587B (ZNF587B) is a novel cisplatin-sensitive gene that was identified in our previous research by using a genome-scale CRISPR-Cas9 knockout library in ovarian cancer (OC) cell lines. ZNF587B belongs to the C2H2-type zinc finger protein (ZFP) family. Many ZFP protein could inhibit tumor development and malignancy. However, the function of ZNF587B remains unknown.
Methods: Quantitative PCR (qPCR) was utilized to compare ZNF587B mRNA expression levels in OC and normal ovarian cell lines. The small interfering RNA (siRNA) and full-length ZNF587B eukaryotic expression plasmid were constructed and transfected into OC cells later. Colony formation, 5-ethynyl-2′-deoxyuridine (EdU) assay, transwell assay, and xenograft experiment were conducted to evaluate the effect of ZNF587B on OC cells.
Results: ZNF587B was downregulated by approximately 43% and 17% in the OC cell lines SKOV3 and A2780, respectively, compared with that in the normal ovarian cell line IOSE80. Overexpression of ZNF587B reduced cell proliferation, colony formation, migration, and invasion, which could be reversed by knockdown of ZNF587B via siRNA. Xenograft experiments also confirmed that ZNF587B could suppress tumor growth. Survival data of OC patients in the SurvExpress database showed that with respect to overall survival, low-risk patients grouped by the prognostic index had a higher expression of ZNF587B and a better prognosis than high-risk group (HR = 1.77, 95% CI: 0.55– 0.70, p = 0.023). Moreover, overexpression of ZNF587B promoted OC cells apoptosis when pretreated with cisplatin.
Conclusion: ZNF587B is a novel potential tumor suppressor of OC and may be a therapeutic target for OC.

Keywords: ZNF587B, C2H2-type zinc finger protein, proliferation, metastasis, ovarian cancer


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]